Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : MEDX ... anybody following? -- Ignore unavailable to you. Want to Upgrade?

To: Icebrg who wrote (609)	9/23/2002 3:02:20 AM
From: Icebrg	Read Replies (2) \| Respond to of 2240

US FDA Approves Genmab's IND Humax-Cd4 to Treat Psoriasis Message 18022378

To: Icebrg who wrote (609)	10/24/2002 4:15:07 AM
From: Icebrg	Read Replies (1) \| Respond to of 2240

Nemod and IDM Announce the Signature of a Joint Research Agreement Thursday October 24, 4:09 am ET PARIS--(BUSINESS WIRE)--October 24, 2002--Immuno-Designed Molecules, S.A. (IDM) and Nemod Immunotherapies AG, a German biotechnology company based in Berlin-Buch, have entered a joint research project to develop new immunotherapy products in cancer treatment. The research project aims at evaluating the potential synergy between some Nemod's antibodies and IDM's MAK® (Monocyte-derived Activated Killer) cells to target and destroy tumor cells. If this evaluation is successful, IDM will be granted an exclusive license with Nemod in the field of ex vivo therapy, allowing IDM to further develop and commercialize several new products to fight cancers such as colon, gastric, breast, prostate and ovarian cancer. One of Nemod's areas of expertise is in glycobiology applied to therapeutic antibodies. Nemod has developed antibodies recognizing unique glycosylation patterns on three pan-carcinomic epitopes or antigens: MUC1, TF-Thomson Friedenreich and Lewis Y. TF is an antigen expressed only on tumors, primarily gastric and colorectal tumors, while MUC1 is over expressed in breast and ovarian cancer. Lewis Y are blood group antigens and are tumor associated antigens found in breast, prostate, hepatocarcinoma and Non Small Cell Lung cancers. "Acces to Nemod antibody technology opens up new avenues in the development of our MAK® based products to destroy cancer cells. This strongly enhances the range of IDM's Cell Drug portfolio under clinical development," said Jean-Loup Romet-Lemonne, President and CEO of IDM.